Back to top

vaccines: Archive

Zacks Equity Research

AstraZeneca (AZN) Q1 Earnings & Sales Beat Estimates, Stock Up

AstraZeneca (AZN) beats first-quarter estimates for earnings and sales, driven by increased demand for its key oncology and rare disease drugs.

SNYNegative Net Change AZNNegative Net Change MRKPositive Net Change AMGNPositive Net Change

Zacks Equity Research

GSK Gears Up for Q1 Earnings: Here's What to Expect

We expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Nucala, Trelegy Ellipta and Shingrix to drive first-quarter sales performance.

GSKPositive Net Change SRPTPositive Net Change CTMXPositive Net Change ARGXPositive Net Change

Zacks Equity Research

GSK Announces FDA Acceptance of New Meningococcal Jab BLA

The approval of GSK's 5-in-1 meningococcal ABCWY vaccine candidate, MenABCWY, could provide the broadest meningococcal serogroup coverage and lead to simplified immunization.

GSKPositive Net Change ANIPPositive Net Change ADMAPositive Net Change ENTXNegative Net Change

Zacks Equity Research

Will Novavax's (NVAX) Strategic Reshaping Curb Cash Burn?

To extend its existing cash runway and curb cash burn, Novavax (NVAX) initiates multiple restructuring initiatives that are aimed at lowering operating expenses and enhancing profitability.

PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change BNTXPositive Net Change

Zacks Equity Research

Moderna (MRNA) Up 6% on Upbeat Data From Cancer Jab Study

Data from an early-stage study shows that treatment with Moderna's (MRNA) experimental cancer therapy achieved positive clinical response in patients with a specific type of head and neck cancer.

MRKPositive Net Change MRNAPositive Net Change ANIPPositive Net Change ADMAPositive Net Change

Zacks Equity Research

Gritstone (GRTS) Plummets 58% in a Week: Here's Why

Gritstone (GRTS) plunges after a mid-stage study evaluating its personalized cancer vaccine in certain patients with colorectal cancer failed to achieve its primary endpoint.

LGNDPositive Net Change ANIPPositive Net Change ADMAPositive Net Change GRTSPositive Net Change

Zacks Equity Research

Moderna (MRNA) Posts Pipeline Progress, Secures Blackstone Funding

Moderna (MRNA) posts data on three experimental vaccines and intends to advance them to late-stage studies. It also secures $750 million in funding from Blackstone to advance its influenza program.

MRNAPositive Net Change ANIPPositive Net Change ADMAPositive Net Change GLPGNegative Net Change

Zacks Equity Research

Moderna (MRNA) Posts Upbeat Data From Next-Gen COVID Jab Study

Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID vaccine induces a more robust immune response compared with its previously approved bivalent COVID vaccine.

PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change BNTXPositive Net Change

Zacks Equity Research

Merck's (MRK) Keytruda-Lynparza Combo Fails 2nd Lung Cancer Study

Merck's attempt to use the Keytruda-Lynparza combination in certain non-small cell lung cancer patients has come up short with a second pivotal study failure.

AZNNegative Net Change MRKPositive Net Change ANIPPositive Net Change ADMAPositive Net Change

Zacks Equity Research

GSK Follows Rivals, to Cap Out-of-Pocket Inhaler Cost in US

GSK plc (GSK) plans to lower the prices of its entire inhaled respiratory products to $35 per month in the United States. The company intends to start this in 2025.

AZNNegative Net Change GSKPositive Net Change TEVAPositive Net Change ADMAPositive Net Change